Methylboronic Acid → [6-(1,1-Dioxo-1lambda6-isothiazolidin-2-yl)pyridin-3-yl][4-(4-methylbenzoyl)piperidin-1-yl]methanone
반응식
Cl[C:2]1[CH:30]=[CH:29][C:5]([C:6]([CH:8]2[CH2:13][CH2:12][N:11]([C:14]([C:16]3[CH:17]=[N:18][C:19]([N:22]4[CH2:26][CH2:25][CH2:24][S:23]4(=[O:28])=[O:27])=[CH:20][CH:21]=3)=[O:15])[CH2:10][CH2:9]2)=[O:7])=[CH:4][CH:3]=1.[CH3:31]B(O)O>>[O:27]=[S:23]1(=[O:28])[CH2:24][CH2:25][CH2:26][N:22]1[C:19]1[N:18]=[CH:17][C:16]([C:14]([N:11]2[CH2:12][CH2:13][CH:8]([C:6](=[O:7])[C:5]3[CH:29]=[CH:30][C:2]([CH3:31])=[CH:3][CH:4]=3)[CH2:9][CH2:10]2)=[O:15])=[CH:21][CH:20]=1참가 물질
3
실험 절차
Using [4-(4-chlorobenzoyl)piperidin-1-yl][6-(1,1-dioxo-1λ6-isothiazolidin-2-yl)pyridin-3-yl]methanone (194 mg) described in Example 116 and methylboronic acid (110 mg) and by the reaction and treatment in the same manner as in Example 115, the title compound (126 mg) was obtained.
출처 및 근거
- ORD 기록
- ord-1e3a0698d74c4c00bfb177bb98f8ad59